Follow
Robert Kratzke
Robert Kratzke
Verified email at umn.edu
Title
Cited by
Cited by
Year
A genomic strategy to refine prognosis in early-stage non–small-cell lung cancer
A Potti, S Mukherjee, R Petersen, HK Dressman, A Bild, J Koontz, ...
New England Journal of Medicine 355 (6), 570-580, 2006
6982006
Human lung carcinomas express Fas ligand
GA Niehans, T Brunner, SP Frizelle, JC Liston, CT Salerno, DJ Knapp, ...
Cancer research 57 (6), 1007-1012, 1997
5321997
Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB.
GA Otterson, RA Kratzke, A Coxon, YW Kim, FJ Kaye
Oncogene 9 (11), 3375-3378, 1994
4991994
The pathogenesis of mesothelioma
M Carbone, RA Kratzke, JR Testa
Seminars in oncology 29 (1), 2-17, 2002
4692002
ERCC1 isoform expression and DNA repair in non–small-cell lung cancer
L Friboulet, KA Olaussen, JP Pignon, FA Shepherd, MS Tsao, S Graziano, ...
New England Journal of Medicine 368 (12), 1101-1110, 2013
3962013
Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer
BA Whitson, RS Andrade, A Boettcher, R Bardales, RA Kratzke, ...
The Annals of thoracic surgery 83 (6), 1965-1970, 2007
3862007
Rb and p16INK4a Expression in Resected Non-Small Cell Lung Tumors
RA Kratzke, TM Greatens, JB Rubins, MA Maddaus, DE Niewoehner, ...
Cancer Research 56 (15), 3415-3420, 1996
3211996
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB …
PA Jänne, X Wang, MA Socinski, J Crawford, TE Stinchcombe, L Gu, ...
Journal of clinical oncology 30 (17), 2063, 2012
320*2012
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non–small-cell lung cancer in four trials of …
FA Shepherd, C Domerg, P Hainaut, PA Jänne, JP Pignon, S Graziano, ...
Journal of clinical oncology 31 (17), 2173, 2013
2982013
Immunohistochemical Detection of the Cyclin-dependent Kinase Inhibitor 2/Multiple Tumor Suppressor Gene 1 (CDKN2/MTS1) Product p16INK4A in Archival …
J Geradts, RA Kratzke, GA Niehans, CE Lincoln
Cancer Research 55 (24), 6006-6011, 1995
2871995
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B
R Govindan, RA Kratzke, JE Herndon, GA Niehans, R Vollmer, D Watson, ...
Clinical Cancer Research 11 (6), 2300-2304, 2005
2862005
A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding.
FJ Kaye, RA Kratzke, JL Gerster, JM Horowitz
Proceedings of the National Academy of Sciences 87 (17), 6922-6926, 1990
2681990
Prognostic effect of tumor lymphocytic infiltration in resectable non–small-cell lung cancer
E Brambilla, G Le Teuff, S Marguet, S Lantuejoul, A Dunant, S Graziano, ...
Journal of Clinical Oncology 34 (11), 1223, 2016
2422016
Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection
MS Tsao, S Marguet, G Le Teuff, S Lantuejoul, FA Shepherd, L Seymour, ...
Journal of clinical oncology 33 (30), 3439, 2015
2192015
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma
R Jagadeeswaran, PC Ma, TY Seiwert, S Jagadeeswaran, O Zumba, ...
Cancer research 66 (1), 352-361, 2006
2172006
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non–small-cell lung cancer …
R Govindan, J Bogart, T Stinchcombe, X Wang, L Hodgson, R Kratzke, ...
Journal of clinical oncology 29 (23), 3120, 2011
2042011
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib+ chemotherapy-Cancer and Leukemia Group B Trial 30203
MJ Edelman, D Watson, X Wang, C Morrison, RA Kratzke, S Jewell, ...
Journal of Clinical Oncology 26 (6), 848-855, 2008
1962008
Immunohistochemical Analysis of the p16INK4 Cyclin-Dependent Kinase Inhibitor in Malignant Mesothelioma
RA Kratzke, GA Otterson, CE Lincoln, S Ewing, H Oie, J Geradts, FJ Kaye
JNCI: Journal of the National Cancer Institute 87 (24), 1870-1875, 1995
1661995
Tumor mutation burden as a biomarker in resected non–small-cell lung cancer
S Devarakonda, F Rotolo, MS Tsao, I Lanc, E Brambilla, A Masood, ...
Journal of Clinical Oncology 36 (30), 2995, 2018
1592018
RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma.
E Shimizu, A Coxon, GA Otterson, SM Steinberg, RA Kratzke, YW Kim, ...
Oncogene 9 (9), 2441-2448, 1994
1571994
The system can't perform the operation now. Try again later.
Articles 1–20